<p>Acumen Pharmaceuticals, Inc.（纳斯达克代码：ABOS - 获取免费报告）内部人士 James Doherty 于 1 月 8 日（星期四）出售了 6,467 股公司的股票。该股票以平均价格 1.82 美元出售，总交易额为 11,769.94 美元。交易完成后，该内部人士持有 54,033 股公司的股票，估值约为 98,340.06 美元。这笔交易代表其持股减少了 10.69%。该交易已在与 SEC 的法律文件中披露，具体内容可通过此链接获取。</p>
<p>获取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
<h2>Acumen Pharmaceuticals 股票表现</h2>
<ul>
<li>MarketBeat 周报 – 7/17 - 7/21</li>
</ul>
<p>在周五的午盘交易中，ABOS 的股价下跌 0.05 美元，达到 1.81 美元。该公司的股票交易量为 284,595 股，而其平均交易量为 263,872 股。该公司的 50 日移动平均价格为 1.95 美元，200 日移动平均价格为 1.68 美元。该股票的市值为 1.0963 亿美元，市盈率为-0.82，贝塔值为 0.23。该公司的债务与股本比率为 0.29，速动比率为 6.02，流动比率为 6.02。Acumen Pharmaceuticals, Inc.的 12 个月最低价为 0.86 美元，最高价为 2.46 美元。</p>
<p>Acumen Pharmaceuticals（纳斯达克代码：ABOS - 获取免费报告）最近于 11 月 12 日（星期三）发布了季度财报。该公司报告每股收益（EPS）为-0.44 美元，超出市场共识预期的-0.63 美元，差额为 0.19 美元。股票分析师预测，Acumen Pharmaceuticals, Inc.在当前年度的每股收益将为-1.56 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>Acumen 因阿尔茨海默病研究而飙升……华尔街预计其股价将翻倍</li>
</ul>
<p>ABOS 近期成为多份分析师报告的主题。华尔街 Zen 在 12 月 21 日（星期日）的一份研究报告中将 Acumen Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。美国银行在 11 月 18 日（星期二）的一份研究报告中将 Acumen Pharmaceuticals 的目标价格从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 10 月 14 日（星期二）的一份研究报告中重申了对 Acumen Pharmaceuticals 的 “卖出（d-）” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 6.75 美元。</p>
<p><strong>查看我们对 ABOS 的最新分析</strong></p>
<h2>对 Acumen Pharmaceuticals 的对冲基金看法</h2>
<p>几家大型投资者最近对该公司的持股进行了调整。AQR Capital Management LLC 在第一季度购买了 Acumen Pharmaceuticals 的新股份，价值约为 46,000 美元。Y Intercept Hong Kong Ltd 在第二季度收购了 Acumen Pharmaceuticals 的新股份，价值约为 291,000 美元。Marshall Wace LLP 在第二季度购买了 Acumen Pharmaceuticals 的新股份，价值为 160,000 美元。Qube Research &amp; Technologies Ltd 在第二季度将其在 Acumen Pharmaceuticals 的持股增加了 160.0%。Qube Research &amp; Technologies Ltd 现在拥有 57,559 股该公司的股票，价值 67,000 美元，此前在上个季度又购买了 35,424 股。最后，Jane Street Group LLC 在第二季度将其在 Acumen Pharmaceuticals 的持股增加了 1,526.0%。Jane Street Group LLC 现在拥有 175,670 股该公司的股票，价值 204,000 美元，此前在上个季度又收购了 164,866 股。机构投资者持有该公司 71.01% 的股票。</p>
<h2>关于 Acumen Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Acumen Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于发现和开发用于神经退行性疾病的口服小分子疗法。该公司利用一种集成了化学蛋白质组学、高通量筛选和计算化学的专有药物发现平台，旨在识别和优化选择性调节病理性蛋白质聚集的化合物。其方法旨在解决阿尔茨海默病、帕金森病、肌萎缩侧索硬化症及相关蛋白病等疾病的基础生物学问题。</p>
<p>该公司的产品管线包括多个处于不同临床前和早期临床开发阶段的主要候选药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Acumen Pharmaceuticals</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>今年你花的最值得的 19 美元。</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Acumen Pharmaceuticals 吗？</h2>
<p>在你考虑 Acumen Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Acumen Pharmaceuticals 并不在名单上。</p>
<p>虽然 Acumen Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABOS

<p>Acumen Pharmaceuticals（纳斯达克代码：ABOS）的内部人士 James Doherty 于 1 月 8 日以每股 1.82 美元的价格出售了 6,467 股公司股票，总计 11,769.94 美元。此次交易后，他持有 54,033 股，反映出其持股减少了 10.69%。该出售在 SEC 文件中披露。Acumen 的股票交易价格下跌至 1.81 美元，市值为 1.0963 亿美元，市盈率为-0.82。分析师对该股票的评级不一，普遍评级为 “适度买入”，目标价格为 6.75 美元</p>

<p>Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider James Doherty sold 6,467 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $1.82, for a total transaction of $11,769.94. Following the completion of the transaction, the insider owned 54,033 shares of the company's stock, valued at approximately $98,340.06. This trade represents a 10.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.（纳斯达克代码：ABOS - 获取免费报告）内部人士 James Doherty 于 1 月 8 日（星期四）出售了 6,467 股公司的股票。该股票以平均价格 1.82 美元出售，总交易额为 11,769.94 美元。交易完成后，该内部人士持有 54,033 股公司的股票，估值约为 98,340.06 美元。这笔交易代表其持股减少了 10.69%。该交易已在与 SEC 的法律文件中披露，具体内容可通过此链接获取。</p>
</div><p>Get <strong>Acumen Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Acumen Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 股票表现</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/17 - 7/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 7/17 - 7/21</li>
</ul>
</div><p>Shares of ABOS traded down $0.05 during mid-day trading on Friday, reaching $1.81. 284,595 shares of the company's stock traded hands, compared to its average volume of 263,872. The business's 50-day moving average price is $1.95 and its 200-day moving average price is $1.68. The stock has a market capitalization of $109.63 million, a P/E ratio of -0.82 and a beta of 0.23. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. Acumen Pharmaceuticals, Inc. has a 12 month low of $0.86 and a 12 month high of $2.46.</p>
<div class="lb-trans"><p>在周五的午盘交易中，ABOS 的股价下跌 0.05 美元，达到 1.81 美元。该公司的股票交易量为 284,595 股，而其平均交易量为 263,872 股。该公司的 50 日移动平均价格为 1.95 美元，200 日移动平均价格为 1.68 美元。该股票的市值为 1.0963 亿美元，市盈率为-0.82，贝塔值为 0.23。该公司的债务与股本比率为 0.29，速动比率为 6.02，流动比率为 6.02。Acumen Pharmaceuticals, Inc.的 12 个月最低价为 0.86 美元，最高价为 2.46 美元。</p>
</div><p>Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.19. Equities analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals（纳斯达克代码：ABOS - 获取免费报告）最近于 11 月 12 日（星期三）发布了季度财报。该公司报告每股收益（EPS）为-0.44 美元，超出市场共识预期的-0.63 美元，差额为 0.19 美元。股票分析师预测，Acumen Pharmaceuticals, Inc.在当前年度的每股收益将为-1.56 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Acumen Soars on Alzheimer's Study...Street Sees It Doubling</li>
</ul>
<div class="lb-trans"><ul>
<li>Acumen 因阿尔茨海默病研究而飙升……华尔街预计其股价将翻倍</li>
</ul>
</div><p>ABOS has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 21st. Bank of America lowered their target price on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Acumen Pharmaceuticals in a research note on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $6.75.</p>
<div class="lb-trans"><p>ABOS 近期成为多份分析师报告的主题。华尔街 Zen 在 12 月 21 日（星期日）的一份研究报告中将 Acumen Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。美国银行在 11 月 18 日（星期二）的一份研究报告中将 Acumen Pharmaceuticals 的目标价格从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 10 月 14 日（星期二）的一份研究报告中重申了对 Acumen Pharmaceuticals 的 “卖出（d-）” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 6.75 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ABOS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ABOS 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Acumen Pharmaceuticals 的对冲基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in the business. AQR Capital Management LLC bought a new stake in shares of Acumen Pharmaceuticals in the 1st quarter worth approximately $46,000. Y Intercept Hong Kong Ltd acquired a new position in Acumen Pharmaceuticals in the second quarter worth approximately $291,000. Marshall Wace LLP bought a new position in shares of Acumen Pharmaceuticals in the second quarter valued at $160,000. Qube Research &amp; Technologies Ltd increased its holdings in shares of Acumen Pharmaceuticals by 160.0% in the second quarter. Qube Research &amp; Technologies Ltd now owns 57,559 shares of the company's stock valued at $67,000 after buying an additional 35,424 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Acumen Pharmaceuticals by 1,526.0% during the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company's stock valued at $204,000 after acquiring an additional 164,866 shares during the last quarter. Institutional investors own 71.01% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近对该公司的持股进行了调整。AQR Capital Management LLC 在第一季度购买了 Acumen Pharmaceuticals 的新股份，价值约为 46,000 美元。Y Intercept Hong Kong Ltd 在第二季度收购了 Acumen Pharmaceuticals 的新股份，价值约为 291,000 美元。Marshall Wace LLP 在第二季度购买了 Acumen Pharmaceuticals 的新股份，价值为 160,000 美元。Qube Research &amp; Technologies Ltd 在第二季度将其在 Acumen Pharmaceuticals 的持股增加了 160.0%。Qube Research &amp; Technologies Ltd 现在拥有 57,559 股该公司的股票，价值 67,000 美元，此前在上个季度又购买了 35,424 股。最后，Jane Street Group LLC 在第二季度将其在 Acumen Pharmaceuticals 的持股增加了 1,526.0%。Jane Street Group LLC 现在拥有 175,670 股该公司的股票，价值 204,000 美元，此前在上个季度又收购了 164,866 股。机构投资者持有该公司 71.01% 的股票。</p>
</div><h2>About Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Acumen Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于发现和开发用于神经退行性疾病的口服小分子疗法。该公司利用一种集成了化学蛋白质组学、高通量筛选和计算化学的专有药物发现平台，旨在识别和优化选择性调节病理性蛋白质聚集的化合物。其方法旨在解决阿尔茨海默病、帕金森病、肌萎缩侧索硬化症及相关蛋白病等疾病的基础生物学问题。</p>
</div><p>The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同临床前和早期临床开发阶段的主要候选药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Acumen Pharmaceuticals</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Best $19 you’ll spend this year.</li>
<li>First Time Since 2007: All Warnings Active</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Acumen Pharmaceuticals</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>今年你花的最值得的 19 美元。</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ABOS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acumen Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Acumen Pharmaceuticals 吗？</h2>
</div><p>Before you consider Acumen Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Acumen Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Acumen Pharmaceuticals 并不在名单上。</p>
</div><p>While Acumen Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Acumen Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

James Doherty 出售了 6,467 股 Acumen Pharmaceuticals（纳斯达克代码：ABOS）的股票